Perspective Therapeutics, Inc.

CATX

Perspective Therapeutics, Inc.

CATX

Insider Sentiment (TTM):

Last Purchase:2025-11-13Last Sale:-Shares Purchased (TTM):20,498Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:78,406,104Shares Outstanding:103,604,000Institutional Ownership Pct.:75.68%

Earnings Market Reaction:

Filing Date:2026-05-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Cash And Cash Equivalents At Carrying Value	54	31	27	29	44	62	226	252	142	9	18	28
Short Term Investments	217	114	147	163	167	165	41	41	39	0	0	0
Notes Receivable Net	-	-	-	-	-	-	-	-	-	0	0	0
Assets Current
Accounts Receivable Net Current	0	0	0	0	0	0	0	0	1	1	2	1
Assets Current	275	148	179	196	216	231	270	294	188	17	22	32
Inventory Net	-	-	-	-	-	-	-	-	-	-	1	1
Assets Of Disposal Group Including Discontinued Op…	-	-	-	-	-	0	0	0	5	5	-	-
Prepaid Expense And Other Assets Current	4	4	4	4	4	4	2	1	1	1	1	1
Assets Noncurrent
Inventory Noncurrent	-	-	-	-	-	-	-	-	-	-	2	2
Intangible Assets Net Excluding Goodwill	-	-	-	-	-	-	-	-	-	-	50	50
Property Plant And Equipment Net	92	77	64	63	61	57	44	15	14	6	7	7
Operating Lease Right Of Use Asset	2	2	2	2	2	2	2	2	1	1	2	1
Restricted Cash And Cash Equivalents Noncurrent	-	-	-	0	0	0	0	0	0	0	0	0
Indefinite Lived Intangible Assets Excluding Goodw…	40	40	50	50	50	50	50	50	50	50	-	-
Goodwill	-	-	-	-	-	0	24	24	24	24	27	27
Other Assets Noncurrent	0	0	0	0	0	0	1	1	0	0	1	1
Disposal Group Including Discontinued Operation As…	-	-	-	-	-	-	-	-	-	0	-	-
Assets	411	267	295	311	329	341	391	386	278	98	111	120
Liabilities And Stockhold…
Accounts Payable And Accrued Liabilities Current	26	21	13	7	9	10	22	6	6	7	4	5
Operating Lease Liability Current	1	1	1	1	1	1	1	1	0	0	0	0
Accounts Payable And Other Accrued Liabilities Cur…	-	-	-	-	-	-	-	-	-	0	0	0
Employee Related Liabilities Current	4	7	7	5	3	5	4	2	-	4	-	-
Liabilities Current
Liabilities Current	31	29	21	13	13	18	28	11	15	16	8	9
Other Liabilities Current	-	-	-	-	-	-	-	-	-	0	0	0
Notes Payable Current	0	0	0	0	0	0	0	0	0	0	-	-
Accrued Vacation Current	-	-	-	-	-	-	-	-	-	0	1	1
Deferred Income Current	-	0	0	0	0	1	1	1	1	0	-	-
Other Notes Payable Current	-	-	-	-	-	-	-	-	-	0	0	0
Liabilities Other Than Lo…
Operating Lease Liability Noncurrent	2	1	1	1	1	1	2	1	1	1	1	1
Long Term Notes Payable	2	2	2	2	2	2	2	2	2	2	2	2
Asset Retirement Obligations Noncurrent	-	-	-	-	-	-	-	-	-	-	1	1
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	0	0	0	5	5	-	-
Deferred Income Noncurrent	27	27	27	27	27	27	27	27	27	0	-	-
Liabilities Of Disposal Group Including Discontinu…	-	-	-	-	-	-	-	-	-	0	-	-
Deferred Income Tax Liabilities Net	2	2	2	2	2	2	5	5	5	5	-	-
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	-	0	-	-
Liabilities	63	60	53	45	45	50	63	45	48	23	12	11
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	1	0	0	0
Additional Paid In Capital Common Stock	709	542	539	537	534	522	520	517	394	228	226	226
Stockholders Equity
Stockholders Equity	347	207	242	266	285	291	328	341	230	75	99	109
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	-0	-	-	-	-	-	-
Retained Earnings Accumulated Deficit	-361	-335	-297	-271	-250	-232	-192	-176	-165	-152	-128	-117
Liabilities And Stockholders Equity	411	267	295	311	329	341	391	386	278	98	111	120
Allowance For Doubtful Accounts Receivable	0	0	0	0	1	1	1	1	1	1	-	-
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	7	7	7	7	7	7	7	7	7	7	7	7
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	750	750	750	750	750	750	750	750	750	750	750	750
Common Stock Shares Issued	684	669	669	668	666	636	608	607	587	564	561	561
Shares Outstanding	114	74	74	74	74	71	68	67	49	56	56	56

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	8.11%	25.68%	70.72%	-	-	-	-21.91%	-6.44%	-	-	-	-
2025	-64.76%	-67.10%	-66.73%	-9.19%	-4.46%	-28.35%	32.27%	46.61%	46.61%	-14.37%	-27.97%	-41.95%
2024	8.70%	169.57%	269.57%	19.41%	4.46%	-5.40%	-23.57%	-31.72%	-21.72%	-14.54%	15.86%	39.65%
2023	-	-	-	-14.58%	-43.75%	-45.83%	-20.00%	0.00%	-13.85%	26.05%	34.45%	-10.08%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	8.75	5.17	8.66	15.09	17.02	12.68	9.60	27.73	12.98	1.07	2.67	3.72
Quick Ratio	8.61	5.05	8.45	14.77	16.70	12.45	9.53	27.62	12.89	1.00	2.43	3.43
Working Capital	243.87M	119.71M	157.88M	182.97M	203.06M	212.93M	242.03M	283.63M	173.70M	1.17M	13.57M	23.37M
Leverage & Debt
Debt to Equity	0.18	0.29	0.22	0.17	0.16	0.17	0.19	0.13	0.21	0.30	0.12	0.11
Interest Coverage TTM	-	-	-	-	-	-	-1,661.05	-1,043.00	-621.59	-474.32	-557.88	-540.37
Debt Ratio	0.15	0.22	0.18	0.14	0.14	0.15	0.16	0.12	0.17	0.23	0.11	0.10
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.02	0.07	0.08	0.08
Days Sales Outstanding TTM	-	-	-	-	-	-	-	119.98	106.96	82.84	87.60	78.61
Receivables Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.04	3.41	4.41	4.17	4.64
Per Share Metrics
Diluted EPS TTM	-1.18	-1.54	-1.49	-1.34	-1.24	-1.30	-0.99	-0.98	-1.31	-1.97	-0.92	-0.63
Free Cash Flow Per Share TTM	-2.34	-3.12	-2.11	-1.01	-0.89	-0.52	-0.30	-1.18	-1.57	-1.72	-0.88	-0.19
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	-	-	-	33.56%	27.13%	-33.65%
Operating Profit Margin TTM	-	-	-	-	-	-	-	-2,841.07%	-1,458.70%	-887.25%	-481.21%	-329.14%
Net Profit Margin TTM	-	-	-	-	-	-	-	-3,421.01%	-1,898.18%	-1,007.75%	-372.35%	-233.36%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-74.72%	-61.96%	-47.34%	-35.56%	-31.35%
Net Income Growth (1Y)	35.63%	35.60%	57.79%	52.69%	38.99%	59.19%	170.54%	270.58%	722.85%	480.37%	256.17%	181.61%
EPS Growth (1Y)	-5.28%	18.36%	50.00%	37.09%	-4.90%	32.26%	114.93%	211.36%	849.79%	670.19%	350.65%	257.15%
Valuation Metrics
P/E TTM	-3.54	-1.78	-2.30	-2.56	-1.71	-2.45	-13.46	-10.17	-9.10	-4.06	-5.85	-21.29
P/B TTM	1.24	0.98	1.05	0.96	0.54	0.71	2.87	1.95	2.56	2.85	1.53	3.45
P/S TTM	-	-	-	-	-	-	-	348.08	172.83	40.87	21.78	49.68
Market Cap	432.03M	202.99M	254.84M	255.37M	154.12M	205.52M	942.90M	664.48M	589.17M	214.11M	151.50M	375.19M
Enterprise Value	379.67M	173.98M	229.71M	228.17M	111.38M	145.61M	718.14M	414.18M	448.76M	206.60M	135.20M	348.57M
Calculated Values
Free Cash Flow TTM	-242.65M	-230.57M	-156.54M	-75.31M	-64.25M	-33.23M	-21.10M	-78.78M	-77.49M	-92.19M	-49.32M	-10.36M
Net Debt	-52.36M	-29.00M	-25.12M	-27.20M	-42.74M	-59.90M	-224.75M	-250.30M	-140.40M	-7.51M	-16.29M	-26.62M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-11-13Purchase

Owner: Hunt, Jonathan Robert

Title: Chief Accounting Officer

Shares: 11,000

Price/Share: $2.03

Value: $22,330.00

Shares Owned: 59,800

Relationship: Officer

Ownership: Direct

2025-11-12Purchase

Owner: Williamson, Robert F Iii

Title: -

Shares: 9,498

Price/Share: $2.10

Value: $19,945.80

Shares Owned: 9,864

Relationship: Director

Ownership: Indirect

2025-03-31Purchase

Owner: Woods, Lori A

Title: -

Shares: 23,475

Price/Share: $2.13

Value: $50,001.75

Shares Owned: 183,460

Relationship: Director

Ownership: Indirect

2025-03-31Purchase

Owner: Williamson, Robert F Iii

Title: -

Shares: 38,145

Price/Share: $2.14

Value: $81,630.30

Shares Owned: 108,982

Relationship: Director

Ownership: Direct

2025-03-28Purchase

Owner: Graham, Juan

Title: Chief Financial Officer

Shares: 33,333

Price/Share: $2.25

Value: $74,999.25

Shares Owned: 35,354

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-11-13	Hunt, Jonathan Robert	Officer	Chief Accounting Officer	Direct	Purchase	11,000	2.03	$22,330.00	59,800	4
2025-11-12	Williamson, Robert F Iii	Director	-	Indirect	Purchase	9,498	2.10	$19,945.80	9,864	4
2025-03-31	Woods, Lori A	Director	-	Indirect	Purchase	23,475	2.13	$50,001.75	183,460	4
2025-03-31	Williamson, Robert F Iii	Director	-	Direct	Purchase	38,145	2.14	$81,630.30	108,982	4
2025-03-28	Graham, Juan	Officer	Chief Financial Officer	Direct	Purchase	33,333	2.25	$74,999.25	35,354	4
2025-03-28	Spoor, Johan M.	Director,Officer	Chief Executive Officer	Direct	Purchase	22,026	2.24	$49,338.24	59,383	4
2024-12-04	Henson, Heidi	Director	-	Indirect	Purchase	25,975	3.85	$100,003.75	25,975	4
2024-12-04	Spoor, Johan M.	Director,Officer	CEO	Direct	Purchase	8,000	3.77	$30,160.00	36,257	4
2024-11-25	Hunt, Jonathan Robert	Officer	Chief Financial Officer	Direct	Purchase	12,829	3.74	$47,980.46	48,800	4
2024-11-25	Williamson, Robert F Iii	Director	-	Direct	Purchase	6,266	3.64	$22,808.24	430,058	4
2024-11-25	Spoor, Johan M.	Director,Officer	CEO	Direct	Purchase	14,500	3.78	$54,810.00	152,072	4
2024-06-17	Hunt, Jonathan Robert	Officer	Chief Financial Officer	Direct	Purchase	1,800	9.82	$17,676.00	35,971	4
2024-06-14	Woods, Lori A	Director	-	Indirect	Purchase	4,587	10.85	$49,768.95	159,985	4
2024-06-13	Spoor, Johan M.	Director,Officer	CEO	Direct	Purchase	100,000	1.17	$117,000.00	137,572	4
2024-06-03	Woods, Lori A	Director	-	Indirect	Purchase	34,246	1.46	$49,999.16	1,553,984	4
2024-05-31	Hunt, Jonathan Robert	Officer	Chief Financial Officer	Direct	Purchase	25,006	1.40	$35,008.40	341,716	4
2024-05-31	Williamson, Robert F Iii	Director	-	Direct	Purchase	55,000	1.38	$75,900.00	423,792	4
2024-05-29	Williamson, Robert F Iii	Director	-	Direct	Purchase	30,031	1.33	$39,941.23	368,792	4
2024-03-06	Lantheus, Alpha Therapy, …	TenPercentOwner	-	Direct	Purchase	60,431,039	0.95	$57,409,487.05	116,773,394	4
2024-01-30	Williamson, Robert F Iii	Director	-	Direct	Purchase	127,206	0.71	$90,316.26	338,761	4
2024-01-29	Williamson, Robert F Iii	Director	-	Direct	Purchase	25,266	0.64	$16,170.24	211,555	4
2024-01-25	Williamson, Robert F Iii	Director	-	Direct	Purchase	22,134	0.49	$10,845.66	75,676	4
2024-01-24	Puhlmann, Markus	Officer	Chief Medical Officer	Direct	Purchase	280,000	0.50	$140,000.00	1,375,425	4
2023-12-21	Williamson, Robert F Iii	Director	-	Indirect	Purchase	3,663	0.33	$1,208.79	3,663	4
2023-12-19	Williamson, Robert F Iii	Director	-	Direct	Purchase	13,680	0.32	$4,377.60	23,680	4
2023-12-19	Puhlmann, Markus	Officer	Chief Medical Officer	Direct	Purchase	400,000	0.34	$136,000.00	1,095,425	4
2023-12-18	Hunt, Jonathan Robert	Officer	Chief Financial Officer	Direct	Purchase	125,000	0.26	$32,500.00	316,710	4
2023-12-15	Woods, Lori A	Director	-	Indirect	Purchase	152,962	0.27	$41,299.74	1,519,738	4
2022-12-05	Hunt, Jonathan Robert	Officer	Chief Financial Officer	Direct	Purchase	32,200	0.38	$12,236.00	191,710	4
2022-11-15	Woods, Lori A	Director,Officer	CEO	Indirect	Purchase	100,000	0.34	$34,000.00	1,147,038	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

75.68%

Inst. Shares: 78,406,104

Shares Outstanding: 103,604,000

2025-12-31

98.09%

Inst. Shares: 72,399,578

Shares Outstanding: 73,813,000

2025-09-30

114.35%

Inst. Shares: 84,957,804

Shares Outstanding: 74,296,000

2025-06-30

113.39%

Inst. Shares: 84,175,108

Shares Outstanding: 74,235,000

2025-03-31

115.38%

Inst. Shares: 83,484,536

Shares Outstanding: 72,357,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	78,406,104	103,604,000	75.68%
2025-12-31	72,399,578	73,813,000	98.09%
2025-09-30	84,957,804	74,296,000	114.35%
2025-06-30	84,175,108	74,235,000	113.39%
2025-03-31	83,484,536	72,357,000	115.38%
2024-12-31	93,802,754	64,425,000	145.60%
2024-09-30	96,565,358	70,629,000	136.72%
2024-06-30	75,811,936	66,648,000	113.75%
2024-03-31	487,863,154	49,510,000	-
2023-12-31	70,645,418	53,528,000	131.98%
2023-09-30	66,558,172	56,110,000	118.62%
2023-06-30	57,461,142	55,998,000	102.61%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Perspective Therapeutics, Inc. (CATX) — SEC Financial Statements & Analysis

Perspective Therapeutics, Inc. (CATX) is a pharmaceutical preparations company, incorporated in DE. Perspective Therapeutics, Inc. trades on NYSE as: CATX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Perspective Therapeutics, Inc. reported a -100.00% year-over-year revenue growth, a Gross Profit Margin of 33.56% (TTM), a Debt-to-Equity ratio of 0.18x, a Price-to-Sales (P/S) ratio of 348.08x (TTM), a Price-to-Book (P/B) ratio of 1.24 (TTM), at a market cap of $432.03M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Gross Profit Margin TTM: 33.56%
Debt To Equity: 0.18x
P/S TTM: 348.08x
P/B TTM: 1.24
Market Cap: $432.03M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Perspective Therapeutics, Inc. in?

Perspective Therapeutics, Inc. (CATX) operates in the Pharmaceutical Preparations industry.

What is CATX's market cap?

Perspective Therapeutics, Inc. (CATX) has a market capitalization of $432.03M as of 2026-03-31.

What exchange does CATX trade on?

Perspective Therapeutics, Inc. (CATX) trades on the NYSE.

Where is Perspective Therapeutics, Inc. incorporated?

Perspective Therapeutics, Inc. is incorporated in DE.

Perspective Therapeutics, Inc. (CATX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.